The research points to a clear behavioural shift: communication is moving beyond text toward images, short videos and ...
1don MSN
Car sales tycoon sues his own £200m company after being ousted over 'offensive' comments to workers
Peter Waddell went from being a homeless teenager on the streets of Glasgow to amassing an estimated £500m fortune as the ...
“He just loves his screen time ," said one of the parents. "When he’s tapping, he’s happy. The only time he’s unhappy is when ...
Hundreds of handmade Valentine’s Day cards delivered more than just messages of love this weekend. They delivered community and hope to children with rare and u ...
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotypeBLA resubmitted to U.S. FDA in January 2026; ...
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...
Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, announced ...
The FDA in July last year declined to approve UX111 for Sanfilippo syndrome, a rare neurodegenerative disorder, citing ...
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel ...
Ollie reports dogs show love through eye contact, affectionate gestures, and emotional connections, demonstrating a genuine ...
Clinical Trials Arena on MSN
Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA
There are currently no approved disease-modifying therapies for MPS IIIA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results